Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Zika virus disease (ZVD) is a mosquito-borne infection caused by Zika virus (ZIKV), primarily transmitted by infected Aedes aegypti and Aedes albopictus. Most infections are asymptomatic or mild, causing rash, fever, conjunctivitis, arthralgia, myalgia and headache. In India, 151 Zika cases were reported across Gujarat, Karnataka and Maharashtra during 2024, highlighting continued transmission within the country. According to the Zika virus epidemiology forecast by Expert Market Research, ZVD remains a public-health concern due to persistent transmission, potential re-emergence, reproductive complications and the lack of an approved vaccine or specific antiviral therapy.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Zika Virus – Number of Cases by Year

Read more about this report - Request a Free Sample

Zika Virus Epidemiology Forecast Report Coverage

Expert Market Research's “Zika Virus Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Zika Virus. It projects the future incidence and prevalence rates of Zika Virus cases across various populations. The study covers age, gender, and type as major determinants of the Zika Virus population. The report highlights patterns in the prevalence of Zika Virus overtime and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Zika Virus in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Zika Virus Understanding: Disease Overview

Zika virus disease (ZVD) remains a mosquito-borne arboviral infection caused by Zika virus (ZIKV), a flavivirus transmitted predominantly by infected Aedes mosquitoes, particularly Aedes aegypti and Aedes albopictus. Infection is frequently asymptomatic or produces a mild self-limited illness characterized by rash, fever, conjunctivitis, arthralgia, myalgia and headache. Its principal public-health importance, however, arises from complications associated with infection during pregnancy and, less frequently, neurological disease including Guillain-Barré syndrome, neuropathy and myelitis.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Region

India

High-Risk Population

Pregnant individuals and their fetuses, newborns exposed in utero, and people living or travelling in areas with active Aedes transmission represent the principal high-risk populations because of congenital and neurological complications.

Key Diagnostic Method

Nucleic-acid amplification testing (NAAT/RT-PCR) during the period of detectable viraemia, supplemented where appropriate by serological testing for ZIKV IgM and confirmatory plaque-reduction neutralization testing.

Major Risk Factor

Exposure to infected Aedes mosquitoes in areas with current or previous ZIKV transmission is the principal risk factor. Pregnancy adds major clinical significance because maternal infection can result in fetal infection and congenital abnormalities.

Major gap in the market

Absence of an approved vaccine or antiviral, imperfect diagnostics caused by flavivirus cross-reactivity, underdiagnosis of asymptomatic infection, limited surveillance, uncertainty around long-term congenital outcomes and inadequate access to specialized pregnancy monitoring remain major gaps.

Zika Virus Epidemiology Perspective

The Zika Virus epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Zika Virus epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Zika Virus and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Unlike chronic diseases, Zika is an acute infectious disease, so incidence and reported case counts are more informative than prevalence. WHO's May 2026 global update documented evidence of current or previous autochthonous transmission in 97 countries and territories, while emphasizing that asymptomatic and mildly symptomatic infections are frequently missed.

Gender-Specific Cases of the Disease

Zika infection affects both males and females, and there is no established biological sex predominance for infection itself. Epidemiological importance differs by reproductive status because infection during pregnancy creates the principal risk for congenital disease.

Age-Specific Cases of the Disease

Zika infection can occur at any age. Clinical burden varies according to age and pregnancy status rather than reflecting a single high-incidence age group. The most consequential age-related population is the fetus and newborn exposed during pregnancy, because congenital infection can produce microcephaly, neurological abnormalities, ocular abnormalities, arthrogryposis and other developmental consequences.

Ethnicity-Wise Cases of the Disease

Contemporary surveillance does not support treating ethnicity as an independent biological risk factor for Zika infection. Apparent population differences primarily reflect geography, vector distribution, travel, exposure patterns, immunity and surveillance intensity. WHO's 2026 map demonstrates that transmission occurs across six WHO regions.

Mortality and Survival Analysis of the Disease

Zika disease is generally not fatal, and mortality is substantially less important than reproductive and neurological morbidity. Current WHO guidance emphasizes congenital Zika syndrome, fetal loss, neurological disease and Guillain-Barré syndrome as the principal severe outcomes. In its May 2026 update, WHO reported low current Zika incidence and identified sustained vigilance rather than high contemporary mortality as the principal public-health requirement.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Asymptomatic Zika Infection

The majority of ZIKV infections are believed to be asymptomatic or minimally symptomatic, creating a major surveillance problem because clinically silent infections can still contribute to sexual transmission and, when occurring during pregnancy, fetal exposure. WHO specifically notes that asymptomatic and mildly symptomatic infections are typically missed by surveillance systems.

Uncomplicated Zika Virus Disease

Symptomatic uncomplicated ZVD generally produces rash, fever, conjunctivitis, arthralgia, myalgia, malaise and headache, with illness usually resolving within several days. WHO's 2025 clinical-management guideline recommends supportive management and careful differentiation from dengue and chikungunya because of overlapping clinical presentations.

Zika Virus Infection During Pregnancy

Maternal infection represents the most clinically consequential disease category because ZIKV can cross the placenta and infect the developing fetus. Current CDC guidance recommends exposure-based testing and enhanced fetal assessment in appropriate pregnant patients.

Congenital Zika Syndrome (CZS)

Congenital Zika syndrome encompasses microcephaly, cerebral structural abnormalities, neurodevelopmental impairment, ocular abnormalities, arthrogryposis, feeding abnormalities and other congenital manifestations associated with fetal ZIKV infection. Contemporary mechanistic reviews continue to identify disruption of neural progenitor-cell development as a central pathogenic mechanism.

Zika Virus – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Zika Virus Epidemiology

The Zika Virus epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

CDC surveillance current through 2 June 2026 recorded 7 travel-associated Zika cases in U.S. states in 2023, 22 in 2024 and 7 in 2025. The same dataset recorded 30 locally acquired cases in U.S. territories in 2023, 10 in 2024 and 1 in 2025; no confirmed Zika disease cases have been reported from U.S. territories since 2019 when interpreted under CDC's current classification framework. No locally acquired state cases were recorded during 2023–2025.

Germany

Germany has no established endemic Zika transmission in the contemporary surveillance period. ECDC surveillance identifies travel-associated Zika as the principal source of European cases, with reporting based on likely place of infection outside mainland EU/EEA. A robust Germany-specific 2023–2026 national case count was not identified in the reviewed evidence and is therefore not fabricated.

France

France remains epidemiologically relevant because its overseas territories contain environments suitable for Aedes transmission, while mainland cases are predominantly travel-associated. ECDC's 2024 travel-associated dataset explicitly separates mainland EU/EEA from outermost regions and includes French territories among the territories requiring distinct surveillance. No single mainland France 2023–2026 incidence estimate was identified in the reviewed sources.

Italy

Italy represents a predominantly travel-associated European Zika market in the current low-transmission period. Contemporary European surveillance continues to monitor imported infections because Aedes vectors are present in parts of Europe, creating a theoretical potential for local establishment under suitable conditions. A nationally representative Italian 2023–2026 Zika incidence estimate was not identified in the reviewed evidence.

Spain

Spain remains relevant because of travel-associated infections and the presence of Aedes vectors in some regions. ECDC's contemporary surveillance records travel-associated cases by likely place of infection and treats Zika as non-endemic in mainland Europe. No directly comparable Spain-wide 2023–2026 case estimate was identified.

United Kingdom

The UK primarily detects imported Zika infections associated with travel to affected tropical and subtropical regions. WHO's February 2026 arboviral update listed travellers returning to the UK from India, Sierra Leone and Thailand among recent Zika-associated travel exposures. A comprehensive national 2023–2026 case series was not identified in the reviewed sources.

Japan

Japan remains an important Asia-Pacific surveillance market because of international travel, Aedes vector ecology and its position within a region with ongoing Zika transmission. Contemporary WHO surveillance confirms continued Zika circulation in parts of Asia, although a Japan-specific national 2023–2026 case total was not identified in the reviewed sources.

India

India experienced a clear resurgence of reported Zika activity in 2024, with 151 Zika disease cases across Maharashtra, Karnataka and Gujarat. Maharashtra reported 140 cases, including 125 in Pune; Karnataka reported 10 and Gujarat 1. No microcephaly or Guillain-Barré syndrome associated with this outbreak had been reported by 31 December 2024.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

According to contemporary 2023–2026 evidence, major gaps remain in the epidemiological characterization, diagnosis, surveillance, prevention and therapeutic development of Zika virus disease. The principal challenge is that reported case counts substantially underestimate actual infection because a large proportion of infections are asymptomatic or mildly symptomatic. WHO's May 2026 update explicitly states that surveillance systems frequently miss these infections and therefore emphasize continued vigilance even during periods of low incidence.

A major opportunity therefore exists in enhanced molecular surveillance. Current public-health systems depend heavily on symptomatic case detection, routine laboratory capacity and notification

Zika Virus: Treatment Overview

The management of Zika virus disease primarily focuses on supportive treatment, prevention of mosquito and sexual transmission, protection of pregnant individuals and fetuses, recognition of neurological complications and long-term monitoring of infants with congenital exposure. There are currently no specific antiviral treatment and no licensed vaccine for Zika prevention. CDC's 2024 treatment guidance recommends rest, adequate fluid intake and symptomatic medication such as acetaminophen for fever and pain. Aspirin and NSAIDs should be avoided until dengue have been excluded because of the risk of bleeding in dengue infection. The 2025 WHO arboviral clinical-management guideline provides the current international framework for Zika alongside dengue, chikungunya and yellow fever. It emphasizes that these diseases often have overlapping early clinical presentations, making laboratory differentiation particularly important.

Key Questions Answered

  • What is the current and projected burden of Zika Virus across the 8 major markets?
  • Which countries across the 8 major markets account for the highest Zika Virus patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of Zika Virus across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Zika Virus across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Zika Virus across the 8 major markets?
  • How do major comorbidities and risk factors influence Zika Virus epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Zika Virus across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Zika Virus landscape across the 8 major markets?
  • Which therapeutic areas linked to Zika Virus are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the Zika Virus epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on Zika Virus epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Zika Virus across the 8 major markets?

Scope of the Zika Virus Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Zika Virus based on several factors.
  • Zika Virus Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Zika Virus report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Zika Virus Therapeutics Market

Allergic Conjunctivitis Drug Pipeline Analysis

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us